13% growth, 55% PAT collapse; regulatory headwind looms
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Q2 delivered 13.1% growth, below claimed 16% on like-for-like basis. PAT miss of 55% YoY significant; management shifted to 'adjusted PAT' narrative, obscuring GAAP reality.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Revenue growth at 13.1% is mid-teens but softer than claimed (16% on adjusted basis). PAT crashed 55% due to regulatory provision (EPCG ₹116 Cr H1) and tax headwinds, masking underlying operational stability (EBITDA margin +84 bps). Regulatory trade margin caps kick Q3, adding near-term drag. Key risk: Price cap impact and competitive pressure on volumes/mix justify cautious near-term stance despite stable margins and multi-year growth trajectory.
₹731.8 Cr
Revenue · +13.1% YoY₹9.3 Cr
Reported PAT · −55.2% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
16% Q2 revenue growth excluding Milann
MISS13.1% YoY on GAAP reported basis (₹731.8 Cr)
EBITDA margin 19.7% with 17% growth
METEBITDA ₹142.5 Cr margin 19.5% consistent, delivery confirmed
Adjusted PAT 30% growth in H1
OVERSTATEDQ2 GAAP PAT ₹9.3 Cr down 55.2% YoY; H1 adjusted masks one-time charges
North Bengaluru ramp improving; target Q4 monthly EBITDA breakeven
PartialQ1 loss ₹7.5 Cr, Q2 loss ₹6 Cr; trajectory reasonable, not yet breakeven
Earnings quality
What changed since the last call
Regulatory trade margin cap introduced
New137 oncology drugs now capped at 30% margin; estimated mid-high single-digit EBITDA impact annually, effective Q3 onwards. Not in prior guidance.
Revenue growth guidance reaffirmed but delivered softer
DowngradeClaim: 16% Q2 growth (like-for-like excl. Milann). Delivered: 13.1% GAAP reported YoY. 3pp miss on topline vs narrative.
North Bengaluru losses narrowing; Q4 breakeven target
NeutralQ1 loss ₹7.5 Cr, Q2 loss ₹6 Cr. Management confident monthly EBITDA breakeven by Q4 FY27 (Jan 2027). Ramp on track but still diluting overall PAT.
The Q&A
Analysts pressed hard on price cap quantification, PAT decline, and growth deceleration. Management held firm on 'mid-teens' and deflected with 'adjusted' metrics. Q&A tone reflected measured confidence, not aggressive. North Bengaluru ramp defended as network synergy, not standalone. Q&A score: 6/10 (adequate, not transparent).
Price cap drug impact — Aditya Chheda, InCred Asset Management
PartialMid-to-high single digit percentage EBITDA impact annually. Effective Q3 (November). Multiple levers (volume, asset utilization, mix) to offset. No change to guidance.
North Bengaluru ramp — Devang Patel, Sameeksha Capital
AnsweredOn track to hit monthly EBITDA breakeven by Q4 FY27. Facility serves new micro-market, positive network synergy on KR Center. Ramp-up improving faster than prior hospitals.
Revenue growth guidance — Sumit Gupta, Antique Stock Broking
DodgedMid-teens guidance stands. Q2 inclusive of some headwinds (mix, regulation). Most clusters performing well; Gujarat deliberate pullback on low-margin payors. Expect gradual improvement.
EPCG provision impact — Aditya Chheda, InCred
AnsweredProvision covers all export obligations. No further material provisions expected. Provision is retroactive; does not impact current cash flow.
Cash flow and OCF conversion — Devang Patel, Sameeksha Capital
AnsweredTemporary: supplier credit terms extended (30 vs 90 days prior), ₹35 Cr AP Government subsidy timing, tax accrual increased. Normalized to ~54%. Expected to improve and revert closer to 80% as one-time items normalize.
Payor mix rationalization — Nitin Agarwal, DAM Capital
AnsweredConscious tradeoff. Non-institutional revenue grew 21% Q2 vs institutional 5%. Clinical talent, infrastructure, and marketing driving premium case mix. Gradual, not abrupt. Focus on sustainable margin expansion.
ARPP growth sustainability — Nitin Agarwal, DAM Capital
PartialCombination of higher robotic surgeries, high-end radiation therapies, payroll mix shift. Guidance reaffirms ARPP growth in line with inflation (~single digit) going forward. Growth across clusters expected to improve over time.
MVT (Medical Value Travel) growth — Gopal Bhatt, Baroda BNP Paribas
AnsweredFY26 ~3%, FY27 H1 ~4–5%, growing at 25% YoY. Geopolitical disturbance did impact, but HCG offsetting through improved screening and affordability messaging. Long-term structural tailwind on cancer incidence and quality care demand.
Guidance
Mid-teens (13–19%) revenue growth FY27 maintained
MediumQ2 delivered 13.1% (low end). Management reaffirmed guidance despite price cap headwind (Q3 effective). Conditional on volume resilience and mix improvement.
21–22% EBITDA margin target within 2 years; 24–25% by year 5
MediumCurrent 19.7% stable. Path to 21–22% requires volume growth + operational efficiency + price cap offset. Ambitious given regulatory headwind introduced post-Q1 guidance.
₹520 bed expansion FY28–29
MediumH1 capex ₹127.9 Cr noted; infrastructure and medical technology upgrades ongoing. Bed additions tracking on plan (25 in Q2, 146 H1).
Risks the call surfaced
Regulatory price cap
High137 oncology drugs (small subset of portfolio but including immunotherapy, high-margin segment) now capped at 30% margin. Estimated mid-to-high single-digit EBITDA impact on annualized basis; effective Q3 FY27.
North Bengaluru ramp-up
MediumHospital lost ₹7.5 Cr in Q1 FY27, ₹6 Cr in Q2. Path to monthly EBITDA breakeven by Q4 FY27 credible but execution-dependent. Any delay extends PAT drag.
PAT volatility from one-time charges
HighQ2 PAT collapsed 55% YoY (₹9.3 Cr) despite 13% revenue growth and stable EBITDA. EPCG provision (₹116 Cr H1), tax swing (₹30 Cr accrual vs ₹99.6 Cr deferred asset prior), and D&A burden responsible. Management's 'adjusted PAT' narrative (₹28.7 Cr H1, +30% growth) diverts from GAAP miss.
Revenue growth deceleration
MediumQ2 GAAP reported revenue growth 13.1% YoY (₹731.8 Cr) vs management claim of 16% on like-for-like basis (excluding Milann divested June 2026). 3 percentage point gap indicates either lower underlying growth or mix headwinds.
Geopolitical headwinds on MVT
LowMVT (Medical Value Travel) growing at 25% YoY but exposed to Middle East and Bangladesh geopolitical risks. Disruptions cited as partial offset to growth. Long-term tailwind but near-term visibility uncertain.
Management
Score 6/10. Moderately transparent. Management provided operational context and flagged regulatory headwind, but shifted to 'adjusted PAT' narrative to soften GAAP collapse. Disclosed one-time items (EPCG, tax swing) but minimized their materiality. Candid on payor rationalization strategy. Operational performance stable (EBITDA margin +84 bps) but revenue growth missed topline claim (13.1% vs 16% adjusted basis, 3pp gap). North Bengaluru ramp-up on trajectory but still loss-making. Bed capacity additions tracking plan (25 Q2, 146 H1). Prior guidance (mid-teens growth, 21–22% margin within 2yr) largely reaffirmed despite new regulatory headwind.
1 · Q3 FY27 (Oct–Dec 2026)
Trade margin cap on 137 oncology drugs effective; mid-high single-digit EBITDA headwind quantified
2 · Q4 FY27 (Jan–Mar 2027)
North Bengaluru target monthly EBITDA breakeven; validates ramp and visibility into FY28 profitability uplift
3 · FY28–29
₹520 bed expansion (Kenya, Kolkata, Nagpur, Bengaluru); capacity growth and geographic diversification underway
Key risk: Price cap impact and competitive pressure on volumes/mix justify cautious near-term stance despite stable margins and multi-year growth trajectory.
Informational and educational content only. Not investment advice.